Rivaroxaban shows promise in ACS secondary prevention in ATLAS
This article was originally published in Scrip
Johnson & Johnson Pharmaceutical Research and Developmentand Bayerare to start a 16,000-patient Phase III study next month of their novel Factor Xa inhibitor rivaroxaban (Xarelto) in the potentially lucrative chronic use indication of ACS prevention based on encouraging Phase II data presented this week at the American Heart Association (AHA) meeting in New Orleans.
You may also be interested in...
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.